Is Merck Paying Peanuts to Viralytics for Full Access to Its Oncolytic Immunotherapy Drug Candidate?

Roche's Tecentriq Approved As Second-Line in Lung Cancer: Implications For Bristol-Myers Squibb

Healthcare Specialist

Winnie Wong

Equity Bottom-Up

<p><a href="https://www.smartkarma.com/entities/15060" target="_blank" data-smartkarma-citation="entities:15060:1">Nektar Therapeutics (NKTR US)</a> 's share price soared 11.02% to $84 on Wednesday after it <a href="http://ir.nektar.com/news-releases/news-release-details/bristol-myers-squibb-and-nektar-therapeutics-announce-global" target="_blank">announced</a> the world's largest ever biotech deal with <a href="https://www.smartkarma.com/entities/1133" target="_blank" data-smartkarma-citation="entities:1133:1">Bristol Myers Squibb Co (BMY US)</a> (up 2.32%) to jointly develop and commercialise Nektar's NKTR-214 with Bristol's blockbuster cancer drug Opdivo and CTLA-4 drug Yervoy.</p><h2>Deal Highlights</h2><p>Netkar will receive total upfront payments of $1.85 billion, consisting of $1 billion in cash and $850 million in equity.  Bristol will purchase 8.3 million shares of Netkar at…</p>

Nektar Therapeutics (NKTR US) 's share price soared 11.02% to $84 on Wednesday after it announced the world's largest ever biotech deal with Bristol Myers Squibb Co (BMY US) (up 2.32%) to jointly develop and commercialise Nektar's NKTR-214 with Bristol's blockbuster cancer drug Opdivo and CTLA-4 drug Yervoy.Deal HighlightsNetkar will receive total upfront payments of $1.85 billion, consisting of $1 billion in cash and $850 million in equity.  Bristol will purchase 8.3 million shares of Netkar at…

Nektar Therapeutics

Nektar: New Pathways To Smarter Deals?